Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

July 21, 2021

Study Completion Date

July 21, 2021

Conditions
Solid Tumors
Interventions
DRUG

Cobimetinib

Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.

Trial Locations (17)

10065

Memorial Sloan Kettering Cancer Center, New York

13385

Hôpital de la Timone, Oncologie Pédiatrique, Marseille

20133

Fondazione IRCCS Istituto Nazionale dei Tumori; Struttura Complessa di Pediatria Oncologica, Milan

28009

Hospital Infantil Universitario Nino Jesus, Madrid

32806

Arnold Palmer Hosp-Children, Orlando

46026

Hospital Universitari i Politecnic La Fe de Valencia, Valencia

48149

Universitaetsklinikum Muenster, Münster

49100

Schneider Children's Medical Center, Petah Tikva

72202

Arkansas Children'S Hospital, Little Rock

75231

Institut Curie, Oncologie Pédiatrique, Paris

78229

University of Texas Health Science Center at San Antonio, San Antonio

94805

Institut Gustave Roussy; Service Pediatrique, Villejuif

02215

Dana Farber Cancer Institute, Boston

08035

Hospital Universitari Vall d'Hebron, Barcelona

L12 2AP

Alderhey Childrens Trust, Liverpool

WC1N 3JH

Great Ormond Street Hospital; Dept. Of Pediatric Oncology, London

NE1 4LP

The Royal Victoria Infirmary; Paediatric and Adolescent Oncology Unit, Newcastle upon Tyne

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02639546 - Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors | Biotech Hunter | Biotech Hunter